+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer

Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer

Journal of Cancer Research and Clinical Oncology 142(6): 1369-1376

Triple-negative breast cancer (TNBC) is characterized by a strong heterogeneity with regard to tumour biology as well as in the clinical course of the disease. This study aimed to analyse whether there are any prognostic factors enabling prediction of the clinical outcome in patients with TNBC. Particularly, the impact of Her2-neu score 0 versus Her2-neu score 1 and 2 on survival was investigated. We retrospectively studied a cohort of 1013 patients with TNBC, diagnosed at seven hospitals between May 2002 and February 2015. We studied the impact of Her2-neu scores (0 vs. 1 or 2 with negative FISH) on disease-free survival (DFS) and overall survival (OS). 1013 patients were included in this study. 447 (44.13 %) of them had a T2-4 tumour. A total of 314 (31.00 %) were nodal-positive and 714 (70.48 %) had high-grade tumours. The Her2-neu score of all participating patients was determined. 588 (58.05 %) of them had a Her2-neu score 0, and 425 (41.95 %) had a score of 1 or 2. This study shows that TNBC patients with a Her2-neu score 0 had a significantly poorer outcome regarding DFS (p = 0.0001) and OS (p = 0.0051) compared to a score of 1 or 2. In contrast, grading did not seem to have any prognostic value for women with TNBC. The Her2-neu score 0 might be considered as an innovative prognostic factor for patients with TNBC indicating poor clinical outcome.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057982866

Download citation: RISBibTeXText

PMID: 27008006

DOI: 10.1007/s00432-016-2146-z

Related references

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients. Bmc Cancer 13: 437, 2013

Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment. Oncotarget 9(72): 33719-33733, 2018

Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer. European Journal of Surgical Oncology 43(10): 1855-1861, 2017

64Psurvival outcome of weak estrogen /progesterone receptor expression in Her2 negative breast cancer is similar to triple negative breast cancer. Annals of Oncology 26(Suppl 9): ix20.1-ix20, 2015

Early placenta insulin-like growth factor indicates highly motile breast cancer cells and poor prognostic Her2-positive and Her2-negative subgroups of breast cancer. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1353, 2003

Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 19(3): 246-248, 2010

Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer. Medicine 94(46): E2066, 2015

Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression. Archives of Gynecology and Obstetrics 290(6): 1221-1229, 2014

Prognostic significance of androgen receptor expression in HER2-positive and triple-negative breast cancer. Polish Journal of Pathology 69(2): 157-168, 2018

Among triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results. Breast Cancer 19(1): 54-59, 2012

Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers. Biomedicine and PharmacoTherapy 70: 190-195, 2015

High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. British Journal of Cancer, 2013

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Research 14(1): R3, 2012

Identification of a metabolic and canonical biomarker signature in Mexican HR+/HER2-, triple positive and triple-negative breast cancer patients. International Journal of Oncology 45(6): 2549-2559, 2014

Elevated preoperative serum levels of collagen I carboxyterminal telopeptide predict better outcome in early-stage luminal-B-like (HER2-negative) and triple-negative subtypes of breast cancer. Tumour Biology 41(5): 1010428319847081, 2019